Incyte Genomics Inc (INCY) Financials
Key financial figures for Incyte Genomics Inc (Q2 2026).
Incyte Corporation reported revenue of $1.67 billion for Q2 FY2026, up 37.7% from the same period a year earlier. Net income was $585.6 million, or $2.81 per share. Operating margin came to 41.69%, against 25.57% a year earlier. Free cash flow for the period was $495.2 million. Across the last 5 reported quarters, quarterly revenue has risen from $1.22 billion in Q2 FY2025 to $1.67 billion in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Incyte Corporation are on the SentiSense financials page.
- Revenue
- $1.7B
- Net Income
- $586M
- EPS
- $2.92
- Total Assets
- $7.9B
- Operating Cash Flow
- $508M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $1.7B | $586M | $2.81 | 41.69% | $495M |
| Q1 FY2026 | $1.3B | $303M | $1.47 | 25.47% | $359M |
| Q4 FY2025 | $1.5B | $299M | $1.46 | 25.48% | $521M |
| Q3 FY2025 | $1.4B | $424M | $2.11 | 31.57% | $545M |
| Q2 FY2025 | $1.2B | $405M | $2.04 | 25.57% | $26M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $5.1B | $1.3B | $6.41 | 26.12% | $1.4B |
| FY2024 | $4.2B | $33M | $0.15 | 2.39% | $249M |
| FY2023 | $3.7B | $598M | $2.65 | 17.73% | $449M |
Frequently asked questions
What was Incyte Corporation's revenue last quarter?
Incyte Corporation reported revenue of $1.67 billion for Q2 FY2026, up 37.7% from the same period a year earlier.
Is Incyte Corporation profitable?
Yes. Incyte Corporation reported net income of $585.6 million for Q2 FY2026, a net margin of 34.98% on revenue.
How has Incyte Corporation's margin trended?
Operating margin was 41.69% in Q2 FY2026, compared with 25.57% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Incyte Corporation generate?
Incyte Corporation generated free cash flow of $495.2 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Incyte Genomics Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.